Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 26, Issue 3, 2008, Pages 468-473

  Belani, Chandra P ^a   Ramalingam, Suresh ^b   Perry, Michael C ^b   LaRocca, Renato V ^b   Rinaldi, David ^b   Gable, Preston S ^b   Tester, William J ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; GEFITINIB; GEMCITABINE; PACLITAXEL; RANITIDINE;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTHRALGIA; ARTICLE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HORMONAL THERAPY; HUMAN; IMMUNOTHERAPY; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEURITIS; NEUROPATHY; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEURITIS; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT; WEAKNESS;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; EPIDERMAL CYST; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38649124303     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1912     Document Type: Article

References (17)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Govindan R, Page N, Morgensztern D, et al: Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: Analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24:4539-4544, 2006
3. Ramalingam S, Belani CP: State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 31:68-74, 2004
4. Belani CP, Lee JS, Socinski MA, et al: Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer. Ann Oncol 16:1069-1075, 2005
5. Kelly K, Crowley J, Bunn PA Jr, et al: Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: A Southwest Oncology Group trial. J Clin Oncol 19:3210-3218, 2001
6. Schiller JH, Harrington D, Belani CP, et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98, 2002
7. Kosmidis P, Mylonakis N, Skarlos D, et al: Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): A multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG). Ann Oncol 11:799-805, 2000
8. Belani CP, Barstis J, Perry MC, et al: Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 21:2933-2939, 2003
9. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
10. Moher D, Schulz KF, Altman DG: The CONSORT statement: Revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357:1191-1194, 2001
11. Altman DG, Schulz KF, Moher D, et al: The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 134:663-694, 2001
12. Vacca A, Ribatti D, Iurlaro M, et al: Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res 11:103-118, 2002
13. Ukena D, Schroeder M, Dittrich I, et al: Phase III randomised trial comparing paclitaxel/carboplatin (PC) every 3 weeks with weekly paclitaxel/carboplatin in patients(pts) with advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:623, 2003 (abstr 2506)
14. Socinski MA, Ivanova A, Bakri K, et al: A randomized phase II trial comparing every 3-weeks carboplatin/paclitaxel with every 3-weeks carboplatin and weekly paclitaxel in advanced non-small cell lung cancer. Ann Oncol 17:104-109, 2006
15. Socinski MA, Schell MJ, Peterman A, et al: Phase III trial comparing a defined duration of therapy versus continuous therapy followed by secondline therapy in advanced-stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 20:1335-1343, 2002
16. Smith IE, O'Brien ME, Talbot DC, et al: Duration of chemotherapy in advanced non-small-cell lung cancer: A randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin. J Clin Oncol 19:1336-1343, 2001
17. Sandler A, Gray R, Perry MC, et al: Paclitaxelcarboplatin alone or with bevacizumab for non-smallcell lung cancer. N Engl J Med 355:2542-2550, 2006